Coherus Will Not Alert Filing Of Pegfilgrastim On-Body

Approval Or Launch Will Trigger Notification To Market

 
• By Dean Rudge
  
Growth Strategy
Coherus is looking to drive revenue growth after a fall in 2022 • Source: Shutterstock

More from Biosimilars

More from Products